Ahammune Biosciences funding, investors and company details

Ahammune Biosciences is an emerging Healthcare startup from Pune, working in the space of Operates as a biotech drug discovery company specializing in therapeutics for autoimmune skin diseases, particularly vitiligo. Founded by Parul Ganju, Krishnamurthy Natarajan.

Company: Ahammune Biosciences Private Limited
Sector: Healthcare
Location: Pune
Founders: Parul Ganju, Krishnamurthy Natarajan
Total funding raised: ₹41.88 Cr

Company overview

Ahammune Biosciences operates as a biotech drug discovery company specializing in therapeutics for autoimmune skin diseases, particularly vitiligo. Its lead candidate, AB1001, is a topical small-molecule gel with a first-in-class mechanism targeting immune pathways to halt depigmentation progression and induce repigmentation, having completed Phase I trials. Operations involve proprietary R&D on skin homeostasis restoration, leveraging interdisciplinary expertise in dermatology and molecular biology for chronic condition treatments.

Funding rounds

Latest round (Series A): $ 5.00 Mn (₹41.88 Cr.), 2024-09-25. Investors: Pi Ventures, Capital 2B, Colossa Ventures, Bipin Agarwal, Unicornus Maximus LLP, Ideaspring Capital, Kotak Alternate Asset Management, Legacy Assets LLP, IAN Group